Several positive elements in Eli Lilly Q3 report, says analyst

An analyst at Sydbank thinks that Eli Lilly's third quarter report includes a number of positive elements, and emphasizes that this could also be good news for competitor Novo Nordisk.

Photo: Mike Blake/Reuters/Ritzau Scanpix

A string of positive results were reported on Tuesday, as US-based Eli Lilly released its financial report for the third quarter of the year. This could also prove good news for its competitor Novo Nordisk, especially when it comes to the sales of its once-weekly GLP-1 drug Ozempic, an analyst from Sydbank assesses.

The Q3 reports shows that Eli Lilly's Ozempic-equivalent drug, Trulicity, has had a revenue growth of 45 percent compared to the same period last year, as revenue for the drug totaled USD 1.6bn. This is USD 100m over the analysts' consensus estimates, as reported by Bloomberg News.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Related articles

Latest news

See all jobs